Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) Exploring clinical development plan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback